Dermata Therapeutics 8/10/2023 Earnings Report

Dermata Therapeutics EPS Results

• Actual EPS: -$9.45
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Dermata Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Dermata Therapeutics Announcement Details

• Date: 8/10/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Dermata Therapeutics (NASDAQ:DRMA) is a clinical‐stage biotechnology company dedicated to developing targeted therapies for inflammatory skin disorders. Leveraging a proprietary intracellular delivery platform, the company aims to address the underlying mechanisms of diseases such as atopic dermatitis, hidradenitis suppurativa and autoimmune blistering disorders. Dermata’s research and development efforts focus on small-molecule and peptide candidates designed to modulate key inflammatory pathways directly within skin cells.

Since its founding, Dermata has advanced a pipeline of product candidates through preclinical studies and early‐stage clinical trials. Lead programs include an intradermal injectable designed to resolve acute inflammation in chronic skin diseases and a topical formulation targeting barrier dysfunction in eczema patients. The company also collaborates with academic institutions and industry partners to strengthen its discovery engine and accelerate the progression of novel assets toward the clinic.

Headquartered in the Boston, Massachusetts area, Dermata Therapeutics serves patient populations in North America and Europe, with plans to expand into additional therapeutic markets as its pipeline matures. The company evolved from earlier life‐science ventures and underwent a strategic rebranding to align its corporate identity with its dermatology focus. Dermata maintains a network of research laboratories and manufacturing partners to support its preclinical and clinical development activities.

Dermata’s executive leadership team brings together experts in dermatological research, drug development and regulatory affairs. Through collaborations with key opinion leaders and patient advocacy groups, the company seeks to address unmet needs in skin disease treatment and improve outcomes for patients worldwide. Dermata continues to leverage its specialized platform technology to create new opportunities for targeted intervention in complex inflammatory skin conditions.